LabCorp’s New FSPx Offering Focuses on Clinical Analytics and Operations

Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletterPharmaceutical Technology\'s In the Lab eNewsletter-10-02-2019
Volume 14
Issue 10

The newly added service will focus on clinical analytics service and clinical operations capabilities.

LabCorp, a life sciences company headquartered in Burlington, NC, now has a laboratory solution added to its functional service provider (FSPx) offering as part of its Covance drug development business. The new service focuses on clinical analytics service and clinical operations capabilities. The company launched the new service in August 2019.

The clinical analytics portion of Laboratory FSPx will deliver global data solutions that enable clients to better manage laboratory data acquisition, data transfer, data transformation, data reconciliation, and site interactions, while the clinical operations sector will include clinical research associates, program managers, program leaders, regulatory staff, clinical trial leads, and clinical trial managers.

“Laboratory FSPx helps clients improve data readiness by integrating FSPx and central laboratory data teams from study setup to completion,” said Bill Hanlon, PhD, group president, Covance Clinical Development and Commercialization Services, in a company press release. “It also enables faster study start-up by implementing standards, lean processes, and blended roles.”

The new service will also help pharmaceutical and biotech companies to optimize costs, improve reconciliation, and streamline their operations. 

“Whether it’s reducing the data reconciliation process time or reducing turnaround times for protocol amendments, Laboratory FSPx’s capabilities at Covance provide end-to-end solutions that help clients manage their laboratory operations,” said Paul Kirchgraber, MD, senior vice president, Clinical Trials Testing Solutions, Covance, in the press release. “The Covance FSPx portfolio of capabilities, now including Laboratory FSPx, meets the growing demands of the industry for flexible, best-in-class solutions for clinical research.”

Source: LabCorp

 

 

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Drug Digest: Focusing on Solid Dosage Trends and Demand
Behind the Headlines, episode 7
Related Content